Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Oct-Dec;23(4):542-9.
doi: 10.1590/s0102-76382008000400015.

Warfarin prevents venous obstruction after cardiac devices implantation in high-risk patients: partial analysis

[Article in English, Portuguese]
Kátia Regina da Silva  1 , Roberto Costa, Roberto Abi Rached, Martino Martinelli Filho, José Guilherme Mendes Pereira Caldas, Francisco César Carnevale, Luiz Felipe Pinho Moreira, Noedir Antonio Groppo Stolf
Affiliations
Randomized Controlled Trial

Warfarin prevents venous obstruction after cardiac devices implantation in high-risk patients: partial analysis

[Article in English, Portuguese]
Kátia Regina da Silva et al. Rev Bras Cir Cardiovasc. 2008 Oct-Dec.

Abstract

Objectives: To evaluate the efficacy of prophylactic use of warfarin in patients with high risk of lead-associated thrombosis.

Methods: Clinical, prospective, randomized and blinded study, in patients submitted to first transvenous leads implantation with LVEF <0.40 and/or previous ipsilateral temporary pacing. After device implantation, patients were randomly assigned to placebo or warfarin. Periodical clinical and laboratorial evaluations were performed to anticoagulant management. After a six-month period, every patient was submitted to a digital subtraction venography. From February 2004 to November 2006, 101 patients underwent randomization. Baseline characteristics were similar in both groups (P=NS).

Results: Venographic analysis showed 31.4% of venous obstructions in patients assigned to warfarin as compared with 57.1% in patients assigned to placebo (RR= 0.57 [95% CI, 0.33 to 0.98]; P=0.015). In the warfarin group, 72% of the PT/INR tests were in therapeutic INR range. Only one patient required warfarin discontinuation and cross-over to placebo group due to gastrointestinal bleeding.

Conclusions: These preliminary results showed that the anticoagulation therapy has been safe and reduced the frequency of venous thrombosis after transvenous cardiac devices implantation in high risk patients.

PubMed Disclaimer

Publication types